BRÈVE

sur AMOEBA (EPA:ALMIB)

Amoéba is entering a new commercial phase with Koppert

Graphique de l'évolution du cours de l'action AMOEBA (EPA:ALMIB).

Amoéba, a French company specializing in microbiological solutions, has received its first order from Koppert, a leader in biocontrol. This event marks Amoéba's transformation into a commercial company. The order, part of a distribution agreement signed in June 2025, covers vineyards and vegetable crops in 18 European countries as well as the United States.

Deliveries will begin in April 2026. The partnership with Koppert envisions a phased approach, targeting priority areas before expanding the product range. The promising collaboration is exemplified by the successful launch of TIAGAN, designed for the vineyard market.

Amoéba structures its activities around its subsidiary Green 4 Agro, headed by Jean-Marc PETAT. This will allow it to respond to the growing demand for environmentally friendly solutions to fungal diseases.

R. E.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de AMOEBA